171 related articles for article (PubMed ID: 36648492)
1. Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer.
Chopra S; Trepka K; Sakhamuri S; Carretero-González A; Zhu J; Egusa E; Zhou J; Leung K; Zhao N; Hooshdaran N; Feng FY; Wells JA; Chou J; Evans MJ
Clin Cancer Res; 2023 Apr; 29(7):1232-1242. PubMed ID: 36648492
[TBL] [Abstract][Full Text] [Related]
2. CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease.
Zhao N; Chopra S; Trepka K; Wang YH; Sakhamuri S; Hooshdaran N; Kim H; Zhou J; Lim SA; Leung KK; Egusa EA; Zhu J; Zhang L; Foye A; Sriram R; Chan E; Seo Y; Feng FY; Small EJ; Chou J; Wells JA; Aggarwal R; Evans MJ
Clin Cancer Res; 2022 Jul; 28(14):3066-3075. PubMed ID: 35604681
[TBL] [Abstract][Full Text] [Related]
3. Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer.
Moroz A; Wang YH; Sharib JM; Wei J; Zhao N; Huang Y; Chen Z; Martinko AJ; Zhuo J; Lim SA; Zhang LH; Seo Y; Carlin S; Leung KK; Collisson EA; Kirkwood KS; Wells JA; Evans MJ
Clin Cancer Res; 2020 Jul; 26(14):3608-3615. PubMed ID: 32341034
[TBL] [Abstract][Full Text] [Related]
4. CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy.
Khan T; Lyons NJ; Gough M; Kwah KKX; Cuda TJ; Snell CE; Tse BW; Sokolowski KA; Pearce LA; Adams TE; Rose SE; Puttick S; Pajic M; Adams MN; He Y; Hooper JD; Kryza T
Theranostics; 2022; 12(16):6915-6930. PubMed ID: 36276654
[No Abstract] [Full Text] [Related]
5. Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
Harrington BS; He Y; Davies CM; Wallace SJ; Adams MN; Beaven EA; Roche DK; Kennedy C; Chetty NP; Crandon AJ; Flatley C; Oliveira NB; Shannon CM; deFazio A; Tinker AV; Gilks CB; Gabrielli B; Brennan DJ; Coward JI; Armes JE; Perrin LC; Hooper JD
Br J Cancer; 2016 Feb; 114(4):417-26. PubMed ID: 26882065
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of tumor metastasis: functional immune modulation of the CUB domain containing protein 1.
Fukuchi K; Steiniger SC; Deryugina E; Liu Y; Lowery CA; Gloeckner C; Zhou B; Kaufmann GF; Quigley JP; Janda KD
Mol Pharm; 2010 Feb; 7(1):245-53. PubMed ID: 19916495
[TBL] [Abstract][Full Text] [Related]
7. Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer.
Harrington BS; He Y; Khan T; Puttick S; Conroy PJ; Kryza T; Cuda T; Sokolowski KA; Tse BW; Robbins KK; Arachchige BJ; Stehbens SJ; Pollock PM; Reed S; Weroha SJ; Haluska P; Salomon C; Lourie R; Perrin LC; Law RHP; Whisstock JC; Hooper JD
Theranostics; 2020; 10(5):2095-2114. PubMed ID: 32104500
[TBL] [Abstract][Full Text] [Related]
8. Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients.
Emerling BM; Benes CH; Poulogiannis G; Bell EL; Courtney K; Liu H; Choo-Wing R; Bellinger G; Tsukazawa KS; Brown V; Signoretti S; Soltoff SP; Cantley LC
Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3483-8. PubMed ID: 23378636
[TBL] [Abstract][Full Text] [Related]
9. The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration.
Dong Y; He Y; de Boer L; Stack MS; Lumley JW; Clements JA; Hooper JD
J Biol Chem; 2012 Mar; 287(13):9792-9803. PubMed ID: 22315226
[TBL] [Abstract][Full Text] [Related]
10. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
Chou J; Trepka K; Sjöström M; Egusa EA; Chu CE; Zhu J; Chan E; Gibb EA; Badura ML; Contreras-Sanz A; Stohr BA; Meng MV; Pruthi RS; Lotan Y; Black PC; Porten SP; Koshkin VS; Friedlander TW; Feng FY
Eur Urol Oncol; 2022 Dec; 5(6):714-718. PubMed ID: 35216942
[TBL] [Abstract][Full Text] [Related]
11. CDCP1 expression is frequently increased in aggressive urothelial carcinoma and promotes urothelial tumor progression.
Saponaro M; Flottmann S; Eckstein M; Hommerding O; Klümper N; Corvino D; Hosni S; Schmidt A; Mönig N; Schmidt D; Ellinger J; Toma M; Kristiansen G; Bald T; Alimonti A; Ritter M; Hölzel M; Alajati A
Sci Rep; 2023 Jan; 13(1):73. PubMed ID: 36593286
[TBL] [Abstract][Full Text] [Related]
12. Regulation of inside-out β1-integrin activation by CDCP1.
Pollan SG; Huang F; Sperger JM; Lang JM; Morrissey C; Cress AE; Chu CY; Bhowmick NA; You S; Freeman MR; Spassov DS; Moasser MM; Carter WG; Satapathy SR; Shah K; Knudsen BS
Oncogene; 2018 May; 37(21):2817-2836. PubMed ID: 29511352
[TBL] [Abstract][Full Text] [Related]
13. CUB domain containing protein 1 (CDCP1) modulates adhesion and motility in colon cancer cells.
Orchard-Webb DJ; Lee TC; Cook GP; Blair GE
BMC Cancer; 2014 Oct; 14():754. PubMed ID: 25301083
[TBL] [Abstract][Full Text] [Related]
14. Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers.
Lim SA; Zhou J; Martinko AJ; Wang YH; Filippova EV; Steri V; Wang D; Remesh SG; Liu J; Hann B; Kossiakoff AA; Evans MJ; Leung KK; Wells JA
J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166238
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer.
Cuda TJ; He Y; Kryza T; Khan T; Tse BW; Sokolowski KA; Liu C; Lyons N; Gough M; Snell CE; Wyld DK; Rose S; Riddell AD; Stevenson ARL; Thomas PA; Clark DA; Puttick S; Hooper JD
Contrast Media Mol Imaging; 2021; 2021():3153278. PubMed ID: 34621145
[TBL] [Abstract][Full Text] [Related]
16. Functional role of cell surface CUB domain-containing protein 1 in tumor cell dissemination.
Deryugina EI; Conn EM; Wortmann A; Partridge JJ; Kupriyanova TA; Ardi VC; Hooper JD; Quigley JP
Mol Cancer Res; 2009 Aug; 7(8):1197-211. PubMed ID: 19671673
[TBL] [Abstract][Full Text] [Related]
17. Suppression of autophagy by CUB domain-containing protein 1 signaling is essential for anchorage-independent survival of lung cancer cells.
Uekita T; Fujii S; Miyazawa Y; Hashiguchi A; Abe H; Sakamoto M; Sakai R
Cancer Sci; 2013 Jul; 104(7):865-70. PubMed ID: 23510015
[TBL] [Abstract][Full Text] [Related]
18. Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma.
Kryza T; Khan T; Puttick S; Li C; Sokolowski KA; Tse BW; Cuda T; Lyons N; Gough M; Yin J; Parkin A; Deryugina EI; Quigley JP; Law RHP; Whisstock JC; Riddell AD; Barbour AP; Wyld DK; Thomas PA; Rose S; Snell CE; Pajic M; He Y; Hooper JD
Theranostics; 2020; 10(9):4116-4133. PubMed ID: 32226543
[No Abstract] [Full Text] [Related]
19. Dysregulated expression of cell surface glycoprotein CDCP1 in prostate cancer.
Yang L; Dutta SM; Troyer DA; Lin JB; Lance RA; Nyalwidhe JO; Drake RR; Semmes OJ
Oncotarget; 2015 Dec; 6(41):43743-58. PubMed ID: 26497208
[TBL] [Abstract][Full Text] [Related]
20. Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model.
Siva AC; Wild MA; Kirkland RE; Nolan MJ; Lin B; Maruyama T; Yantiri-Wernimont F; Frederickson S; Bowdish KS; Xin H
Cancer Res; 2008 May; 68(10):3759-66. PubMed ID: 18483259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
